BSX is currently developing the following drugs: Agent Dcb 40 Mm, Therasphere Gbm, Therasphere Y-90 Glass Microsphere Therapy, Durvalumab (Imfinzi) Immunotherapy, Tremelimumab Immunotherapy. These drug candidates are in various stages of clinical development as the company works toward FDA approval.